Dr Atul Verma (Medical Director, Heart Rhythm Program, Southlake Regional Health Centre, Newmarket, ON, Canada) spoke to us at Heart Rhythm 2019 about the current unmet needs in substrate and trigger ablation, and the findings of the STAR AF II trial.
Speaker’s disclosures: Atul Verma has received research grants from Bayer, BMS, Medtronic and Bionsense Webster, and honorarium from Abbott, Bayer and Servier.
Questions:
1. What are the current unmet needs in substrate and trigger ablation? (0:06)
2. What were the findings of the Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF II) trial? (0:56)
3. How should physicians assess the need for ablation in patients with persistent atrial fibrillation, post pulmonary vein isolation? (1:57)
4. What are your highlights from Heart Rhythm 2019? (3:26)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
